Although HER2 targeted therapies have dramatically shifted the treatment landscape-reducing the risk of recurrence by 50% and improving survival by 33%-these therapies are often associated with cardiotoxicity.įollowing neoadjuvant HER2-targeted therapy, adjuvant T-DM1 is the current standard of care in this setting. HER2-positive breast cancers represent 20% of breast cancer and are linked to aggressive clinical behavior and poor prognoses, according to the study authors. Unfortunately, 1 patient had to discontinue radiation early because of grade 3 skin dermatitis. Most experienced grade 2 skin dermatitis, although 1 patient developed grade 3 skin dermatitis. According to the study authors, most patients tolerated radiation. 343).Īmong 16 patients who were evaluable for GLS measurements, there were no statistical differences with concurrent radiation ( P =. In addition, paired t-testing revealed that there was no statistically significant difference in ejection fraction after radiation ( P =. The median preradiation ejection fraction was 60% and the median ejection fraction radiation was 61%. In an analysis of 32 patients, 2 (6%) experienced a drop in ejection fraction following radiation. Adjuvantado-trastuzumab emtansine (T-DM1 Kadcyla) with concurrent radiotherapy did not lead to a significant drop in ejection fraction or global longitudinal strain(GLS) in patients with early-stage, HER2-positive breast cancer, according to a poster that was presented at the 2022 San Antonio Breast Cancer Symposium.
0 Comments
Leave a Reply. |